NO20066074L - Irinotecanpreparat - Google Patents

Irinotecanpreparat

Info

Publication number
NO20066074L
NO20066074L NO20066074A NO20066074A NO20066074L NO 20066074 L NO20066074 L NO 20066074L NO 20066074 A NO20066074 A NO 20066074A NO 20066074 A NO20066074 A NO 20066074A NO 20066074 L NO20066074 L NO 20066074L
Authority
NO
Norway
Prior art keywords
irinotecan
mol
closed
salt
water phase
Prior art date
Application number
NO20066074A
Other languages
English (en)
Inventor
Seigo Sawada
Takeshi Matsuzaki
Keisuke Yoshino
Shigenori Nozawa
Masashi Isozaki
Ikuo Kato
Original Assignee
Yakult Honsha Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yakult Honsha Kk filed Critical Yakult Honsha Kk
Publication of NO20066074L publication Critical patent/NO20066074L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Irinotekanpreparat som har irinotekan og/eller et salt derav sterkt båret av en lukket vesikkelbærer, som oppviser en bemerkelsesverdig forlenget retensjon i blod sammenlignet med den til vanlige irinotekanliposompreparater, og som er i stand til å være til stede i blod i et langvarig tidsrom. Det er tilveiebrakt et irinotekanpreparat som omfatter lukkede vesikler dannet av en lipidmembran hvori irinotekan og/eller et salt derav er innelukket ved en konsentrasjon på minst 0,07 mol/mol (legemiddel-mol/totalmembranlipid-mol). Irinotekanpreparatet har fortrinnsvis en ionegradient mellom en indre vannfase og en ytre vannfase i de lukkede vesikler. De lukkede vesikler er fortrinnsvis liposomer, og liposomene har fortrinnsvis bare den utvendige overflate derav modifisert med et overflatemodifiseringsmiddel som inneholder en hydrofil polymer.
NO20066074A 2004-06-01 2006-12-29 Irinotecanpreparat NO20066074L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004163742 2004-06-01
PCT/JP2005/009953 WO2005117878A1 (ja) 2004-06-01 2005-05-31 イリノテカン製剤

Publications (1)

Publication Number Publication Date
NO20066074L true NO20066074L (no) 2007-02-28

Family

ID=35462721

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20066074A NO20066074L (no) 2004-06-01 2006-12-29 Irinotecanpreparat

Country Status (24)

Country Link
US (1) US7846473B2 (no)
EP (1) EP1752150B1 (no)
JP (1) JP4885715B2 (no)
KR (1) KR100889139B1 (no)
CN (1) CN1960729B (no)
AP (1) AP2255A (no)
AR (1) AR049137A1 (no)
AU (1) AU2005249314B2 (no)
BR (1) BRPI0511753A (no)
CA (1) CA2567857C (no)
CR (1) CR8768A (no)
EA (1) EA011612B1 (no)
EC (1) ECSP067041A (no)
ES (1) ES2594621T3 (no)
GE (1) GEP20094620B (no)
IL (1) IL179558A0 (no)
MX (1) MXPA06013874A (no)
NO (1) NO20066074L (no)
NZ (1) NZ551748A (no)
TN (1) TNSN06395A1 (no)
TW (1) TWI362931B (no)
UA (1) UA85099C2 (no)
WO (1) WO2005117878A1 (no)
ZA (1) ZA200610204B (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101376895B1 (ko) 2004-05-03 2014-03-25 헤르메스 바이오사이언스, 인코포레이티드 약물 전달에 유용한 리포좀
US20090196918A1 (en) * 2008-02-01 2009-08-06 University Of Kentucky Research Foundation Liposomal formulations of hydrophobic lactone drugs in the presence of metal ions
AU2009249403A1 (en) * 2008-05-19 2009-11-26 The University Of North Carolina At Chapel Hill Methods and compositions comprising novel cationic lipids
JPWO2010058840A1 (ja) * 2008-11-20 2012-04-19 テルモ株式会社 リポソームからの薬物放出手段および放出性評価法
RU2526114C2 (ru) 2009-12-03 2014-08-20 Цзянсу Хэнжуй Медицин Ко., Лтд. Липосомы иринотекана или его солей, способ их получения
CN103120645B (zh) * 2009-12-03 2015-03-11 江苏恒瑞医药股份有限公司 伊立替康或盐酸伊立替康脂质体及其制备方法
US10980798B2 (en) 2011-11-03 2021-04-20 Taiwan Liposome Company, Ltd. Pharmaceutical compositions of hydrophobic camptothecin derivatives
CA2850955C (en) 2011-11-03 2019-11-19 Taiwan Liposome Company, Ltd. Pharmaceutical compositions of hydrophobic camptothecin derivatives
KR101842279B1 (ko) * 2012-03-29 2018-03-26 우석대학교 산학협력단 이리노테칸의 안정성증진을 위한 주사제용 조성물
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
EA023079B1 (ru) * 2012-12-24 2016-04-29 Общество С Ограниченной Ответственностью "Технология Лекарств" Способ получения липосомальной формы иринотекана (варианты)
CN104906586A (zh) * 2014-03-10 2015-09-16 中国科学院上海药物研究所 一种盐酸伊立替康复合磷脂组合物、制备方法及其应用
CN105796495B (zh) * 2014-12-29 2020-10-23 南京绿叶制药有限公司 一种盐酸伊立替康脂质体药物组合物及其制备方法
CN105982857B (zh) * 2015-02-09 2019-03-08 湖南科伦药物研究有限公司 一种盐酸伊立替康脂质体组合物及其制备方法
ES2589320B2 (es) * 2015-04-14 2017-06-01 Universidad Politécnica de Madrid Sistema de compartimentación de espacios con membranas enrollables
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
KR101646181B1 (ko) 2015-08-18 2016-08-05 한양대학교 에리카산학협력단 이리노테칸 함유 이중역상 온도감응성 수용성 겔 조성물
CA2992789A1 (en) 2015-08-20 2017-02-23 Ipsen Biopharm Ltd. Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
EP3791876A1 (en) 2015-08-21 2021-03-17 Ipsen Biopharm Ltd. Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
MX2018004328A (es) 2015-10-16 2018-08-01 Ipsen Biopharm Ltd Composiciones farmaceuticas estabilizantes de camptotecina.
SG11201903615WA (en) * 2016-11-02 2019-05-30 Ipsen Biopharm Ltd Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)
KR102066402B1 (ko) * 2017-12-22 2020-01-15 대화제약 주식회사 이리노테칸 또는 그의 약제학적으로 허용가능한 염을 포함하는 경구투여용 약제학적 조성물
CN109260155B (zh) 2018-11-05 2021-04-06 杭州高田生物医药有限公司 伊立替康脂质体制剂及其制备与应用
KR102185475B1 (ko) * 2019-06-20 2020-12-02 대화제약 주식회사 이리노테칸 자유 염기를 포함하는 경구투여용 약학 조성물
AU2022367142A1 (en) * 2021-10-15 2024-03-28 Kunshan Xinyunda Biotech Co., Ltd. Composition containing antitumor drug, and preparation method therefor and use thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
EP0721328A4 (en) 1993-09-27 1997-09-17 Smithkline Beecham Corp CAMPTOTHECIN FORMULATIONS
US5827533A (en) 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
US6090407A (en) 1997-09-23 2000-07-18 Research Development Foundation Small particle liposome aerosols for delivery of anti-cancer drugs
DK1121102T3 (da) 1998-09-16 2003-08-11 Alza Corp Liposomindesluttede topoisomeraseinhibitorer
ES2327025T3 (es) 1999-06-25 2009-10-23 Terumo Kabushiki Kaisha Liposomas.
JP2001064158A (ja) * 1999-06-25 2001-03-13 Terumo Corp リポソーム
US6352996B1 (en) 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
ATE309787T1 (de) * 2000-06-30 2005-12-15 Inex Pharmaceuticals Corp Verbesserte liposomale camptothecine und deren verwendungen
JP4778679B2 (ja) * 2001-10-03 2011-09-21 セレーター ファーマシューティカルズ インコーポレイテッド 併用薬剤を送達するための組成物
IL161187A0 (en) 2001-10-03 2004-08-31 Celator Technologies Inc Liposome compositions containing metal ions and therapeutic agents
JP4555569B2 (ja) * 2001-11-13 2010-10-06 セレーター ファーマシューティカルズ， インコーポレイテッド 増強された血中安定性を有する脂質キャリア組成物
DE60222580T2 (de) * 2001-11-13 2008-06-12 Celator Pharmaceuticals, Inc. Lipidträgerzusammensetzungen und verfahren zur verbesserten wirkstoffzurückhaltung
EP1608338A1 (en) * 2003-04-02 2005-12-28 Celator Technologies Inc. Pharmaceutical compositions containing active agents having a lactone group and transition metal ions
KR101376895B1 (ko) 2004-05-03 2014-03-25 헤르메스 바이오사이언스, 인코포레이티드 약물 전달에 유용한 리포좀
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain

Also Published As

Publication number Publication date
EA011612B1 (ru) 2009-04-28
EA200602246A1 (ru) 2007-04-27
ES2594621T3 (es) 2016-12-21
JP4885715B2 (ja) 2012-02-29
AU2005249314A1 (en) 2005-12-15
CR8768A (es) 2007-08-28
KR20070037440A (ko) 2007-04-04
EP1752150A1 (en) 2007-02-14
CA2567857A1 (en) 2005-12-15
ZA200610204B (en) 2008-01-30
BRPI0511753A (pt) 2008-01-02
US7846473B2 (en) 2010-12-07
AU2005249314B2 (en) 2008-09-11
GEP20094620B (en) 2009-02-25
AP2255A (en) 2011-07-21
AR049137A1 (es) 2006-06-28
AP2006003837A0 (en) 2006-12-31
KR100889139B1 (ko) 2009-03-17
TNSN06395A1 (en) 2008-02-22
CA2567857C (en) 2009-12-22
CN1960729B (zh) 2012-04-11
JPWO2005117878A1 (ja) 2008-04-03
WO2005117878A1 (ja) 2005-12-15
ECSP067041A (es) 2006-12-29
US20080069868A1 (en) 2008-03-20
EP1752150A4 (en) 2012-06-20
CN1960729A (zh) 2007-05-09
IL179558A0 (en) 2007-07-04
EP1752150B1 (en) 2016-08-31
NZ551748A (en) 2010-02-26
TWI362931B (en) 2012-05-01
TW200600095A (en) 2006-01-01
UA85099C2 (en) 2008-12-25
MXPA06013874A (es) 2007-04-25

Similar Documents

Publication Publication Date Title
NO20066074L (no) Irinotecanpreparat
Todo et al. Permeation pathway of macromolecules and nanospheres through skin
Broekemeier et al. Proton selective substate of the mitochondrial permeability transition pore: regulation by the redox state of the electron transport chain
Xiang et al. Transbuccal delivery of 2′, 3′-dideoxycytidine: in vitro permeation study and histological investigation
AU4711296A (en) Method for loading lipid vesicles
KOBAYASHI et al. Feasibility of use of several cardiovascular agents in transdermal therapeutic systems with l-menthol-ethanol system on hairless rat and human skin
Dante et al. Insertion of externally administered amyloid β peptide 25− 35 and perturbation of lipid bilayers
García-Linares et al. Role of the tryptophan residues in the specific interaction of the sea anemone Stichodactyla helianthus’s actinoporin Sticholysin II with biological membranes
Schrier Pathobiology of thalassemic erythrocytes
CA2534551A1 (en) Cosmetic composition to assist transport of oxygen into the skin
Daniels et al. Glucose and glycerol compared as osmotic agents for peritoneal dialysis
ITMI20020189A1 (it) Composizione per uso farmaceutico o dietetico per contrastare la caduta dei capelli
CN101199273B (zh) 一种新型多器官储存保护液
Robert et al. Elastin in blood vessels
Haralampiev et al. The interaction of sorafenib and regorafenib with membranes is modulated by their lipid composition
D’Errico et al. Interaction of a peptide derived from glycoprotein gp36 of feline immunodeficiency virus and its lipoylated analogue with phospholipid membranes
Ichihara et al. Trehalose liposomes suppress the growth of tumors on human lung carcinoma-bearing mice by induction of apoptosis in vivo
Tavano et al. New sucrose cocoate based vesicles: preparation characterization and skin permeation studies
Matsuo et al. Possible effects of hepatocyte growth factor for the prevention of peritoneal fibrosis
Fischer et al. Uptake of codeine into intestinal epithelial (Caco-2) and brain endothelial (RBE4) cells
HUP0001769A2 (hu) Lakrofil készítmény alkalmazása gyógyászati hatóanyag-tartalmú szemcseppekben
Vitiello et al. The iAβ5p β-breaker peptide regulates the Aβ (25–35) interaction with lipid bilayers through a cholesterol-mediated mechanism
Flanigan How should dialysis fluid be individualized for the chronic hemodialysis patient?
Hoshi et al. Hydrogen ion-coupled transport of D-glucose by phlorizin-sensitive sugar carrier in intestinal brush-border membranes
Donovan et al. Transbilayer movement of fully ionized taurine-conjugated bile salts depends upon bile salt concentration, hydrophobicity, and membrane cholesterol content

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application